ECG
ECG People diagnosed with a life-threatening cardiac condition have been given new hope, thanks to a ground-breaking new drug that protects the heart developed by researchers from UCL and the Royal Free Hospital. The trial results, published in The New England Journal of Medicine , show that patients with transthryretin amyloid cardiomyopathy (ATTR-CM) benefitted significantly when they took the drug Acoramidis. ATTR-CM is the most commonly diagnosed form of amyloidosis. If left untreated, clumps of protein build up on the heart that prevent it from working properly, ultimately leading to heart failure and death within three to six years. In the trial, 632 patients with ATTR-CM were given Acoramidis or a placebo for 30 months. The drug works by stabilising the transthyretin protein to stop it falling apart, thereby preventing amyloid formation. Results indicated that the drug had clear benefits in terms of mortality, morbidity and physical function compared to the placebo.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
